Mexico Glp-1 Receptor Agonist Market Size & Outlook
Mexico glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Mexico glp-1 receptor agonist market highlights
- The Mexico glp-1 receptor agonist market generated a revenue of USD 235.0 million in 2023 and is expected to reach USD 884.0 million by 2030.
- The Mexico market is expected to grow at a CAGR of 20.8% from 2024 to 2030.
- In terms of segment, trulicity was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 235.0 million |
| Market revenue in 2030 | USD 884.0 million |
| Growth rate | 20.8% (CAGR from 2023 to 2030) |
| Largest segment | Trulicity |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.6% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 133,237.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Trulicity was the largest segment with a revenue share of 30.17% in 2023. Horizon Databook has segmented the Mexico glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
The GLP-1 receptor agonist market in Mexico is positioned for robust growth driven by a high disease burden. According to the International Diabetes Federation, in 2021, around 17% of the total population in Mexico, accounting for 1 in 6 individuals or 14 million people, were suffering from diabetes, and around 32% of the total population were suffering from obesity.
With such high incidence and mortality rates, Mexican market for GLP-1 agonists is expected to expand as it seeks effective treatments for these conditions. The competitive landscape includes local biotech firms and international pharmaceutical companies, which are capitalizing on Mexico's favorable regulatory environment and increasing healthcare investments.
Key players in the market are focusing on introducing their flagship GLP-1 receptor agonists like Ozempic (semaglutide), Trulicity (dulaglutide), and Mounjaro (tirzepatide) to the Mexican market. Moreover, the market players are leveraging their global expertise to navigate the local regulatory landscape and adapt their strategies to the Mexican healthcare system.
Reasons to subscribe to Mexico glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Mexico glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Mexico GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
